Captrust Financial Advisors Lowers Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Captrust Financial Advisors cut its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 136,586 shares of the company's stock after selling 18,626 shares during the quarter. Captrust Financial Advisors' holdings in Novo Nordisk A/S were worth $11,749,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in NVO. Center for Financial Planning Inc. lifted its holdings in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares in the last quarter. Transce3nd LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $39,000. Finally, Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.8 %

Shares of NYSE NVO opened at $67.49 on Thursday. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a market capitalization of $302.88 billion, a P/E ratio of 20.51, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a 50 day simple moving average of $70.14 and a 200-day simple moving average of $86.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Analyst Upgrades and Downgrades

Several research firms recently commented on NVO. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and an average price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.